Neogen Co. (NASDAQ:NEOG – Get Free Report) CEO John Edward Adent acquired 14,500 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was acquired at an average cost of $13.80 per share, with a total value of $200,100.00. Following the transaction, the chief executive officer now directly owns 216,477 shares of the company’s stock, valued at approximately $2,987,382.60. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Neogen Price Performance
Shares of NEOG stock opened at $14.61 on Thursday. The company has a market capitalization of $3.16 billion, a PE ratio of 1,461.00 and a beta of 1.21. The firm has a fifty day simple moving average of $16.10 and a 200-day simple moving average of $15.17. The company has a current ratio of 3.82, a quick ratio of 2.59 and a debt-to-equity ratio of 0.28. Neogen Co. has a twelve month low of $11.46 and a twelve month high of $20.89.
Neogen (NASDAQ:NEOG – Get Free Report) last announced its earnings results on Thursday, October 10th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $217.00 million during the quarter, compared to analysts’ expectations of $215.05 million. Neogen had a negative net margin of 1.02% and a positive return on equity of 3.09%. Neogen’s revenue for the quarter was down 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 earnings per share. Equities research analysts anticipate that Neogen Co. will post 0.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Neogen to a “sell” rating in a research report on Monday, September 30th. Piper Sandler increased their price objective on shares of Neogen from $17.00 to $17.50 and gave the stock a “neutral” rating in a research report on Tuesday, August 6th.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Featured Articles
- Five stocks we like better than Neogen
- How Can Investors Benefit From After-Hours Trading
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to buy stock: A step-by-step guide for beginnersÂ
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.